273 related articles for article (PubMed ID: 20872853)
1. DNA repair and personalized breast cancer therapy.
Li SX; Sjolund A; Harris L; Sweasy JB
Environ Mol Mutagen; 2010; 51(8-9):897-908. PubMed ID: 20872853
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer subtypes: morphologic and biologic characterization.
Masood S
Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
[TBL] [Abstract][Full Text] [Related]
3. DNA repair pathways in breast cancer: from mechanisms to clinical applications.
Tufail M
Breast Cancer Res Treat; 2023 Aug; 200(3):305-321. PubMed ID: 37289340
[TBL] [Abstract][Full Text] [Related]
4. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
5. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment approaches for triple-negative breast cancer.
Telli ML; Ford JM
Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
[TBL] [Abstract][Full Text] [Related]
7. DNA repair and damage pathways in breast cancer development and therapy.
Majidinia M; Yousefi B
DNA Repair (Amst); 2017 Jun; 54():22-29. PubMed ID: 28437752
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
9. The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
Afzali F; Akbari P; Naderi-Manesh H; Gardaneh M
Breast Cancer Res Treat; 2019 Jun; 175(2):277-286. PubMed ID: 30810866
[TBL] [Abstract][Full Text] [Related]
10. DNA damage repair functions and targeted treatment in breast cancer.
He C; Kawaguchi K; Toi M
Breast Cancer; 2020 May; 27(3):355-362. PubMed ID: 31898156
[TBL] [Abstract][Full Text] [Related]
11. DNA damage repair in breast cancer and its therapeutic implications.
Ali R; Rakha EA; Madhusudan S; Bryant HE
Pathology; 2017 Feb; 49(2):156-165. PubMed ID: 28034453
[TBL] [Abstract][Full Text] [Related]
12. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
13. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.
Nowsheen S; Whitley AC; Yang ES
Curr Mol Med; 2012 Jul; 12(6):788-803. PubMed ID: 22292444
[TBL] [Abstract][Full Text] [Related]
14. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
Jhan JR; Andrechek ER
Oncogene; 2017 Jun; 36(25):3553-3561. PubMed ID: 28135251
[TBL] [Abstract][Full Text] [Related]
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
16. Personalized therapy for breast cancer: a dream or a reality?
Zardavas D; Pugliano L; Piccart M
Future Oncol; 2013 Aug; 9(8):1105-19. PubMed ID: 23902243
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNAs engender drug resistance to different subtypes of treatments of breast cancers and may provide a "next generation" therapy option.
Chen WT; Wu HT; Shen JX; Ye QQ; Zhang ML; Chen WJ; Liu J
Discov Med; 2020; 29(156):27-39. PubMed ID: 32598860
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification of infiltrating breast cancer: toward personalized therapy.
Trop I; LeBlanc SM; David J; Lalonde L; Tran-Thanh D; Labelle M; El Khoury MM
Radiographics; 2014; 34(5):1178-95. PubMed ID: 25208275
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
